(88 days)
Not Found
No
The summary describes a laser system for ophthalmic procedures and does not mention any AI or ML components or functionalities.
Yes
The device is indicated for photodisruption and photocoagulation of ocular tissue to treat various conditions like posterior capsulotomy, pupillary membranectomy, diabetic retinopathy, and glaucoma, which are therapeutic interventions.
No
The provided text explicitly states that the Coherent Popeye Ophthalmic Laser is indicated for "photodisruption of ocular tissue using laser energy" and "treatment of ocular pathology," which are therapeutic rather than diagnostic actions.
No
The device description explicitly lists hardware components such as a laser/optics module, a laser power supply/control console, a remote control unit, a covered footswitch, and a laserized mirror. This indicates it is a hardware device that utilizes laser technology.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Device Function: The Coherent Popeye Ophthalmic Laser and its associated components are used to directly treat ocular tissue using laser energy. They are therapeutic devices, not diagnostic ones.
- Intended Use: The intended uses clearly describe procedures performed on the patient's eye (photodisruption, photocoagulation, retinopexy, etc.) for treatment purposes.
- Device Description: The description focuses on the components that deliver laser energy for treatment.
Therefore, this device falls under the category of therapeutic medical devices, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
- The Coherent Popeye Ophthalmic Laser is indicated for use in photodisruption of ocular tissue using laser energy emitted by a Nd: YAG laser. These indications include: discission of the posterior capsule of the eye (posterior capsulotomy) discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients.
- The Coherent Popeye Ophthalmic Laser when used in combination with the Coherent Ultima 2000 or Ultima 2000SE has the capability of delivering argon laser energy. The Coherent Ultima 2000 and Ultima 2000SE are indicated for use in the treatment of ocular pathology using blue-green and green argon laser energy.
- The Coherent Popeye Ophthalmic Laser in Combination with the Ultima 2000 or Ultima 2000SE Argon Photocoagulator is indicated for:
a. Popeye Nd: Y AG 1064 nm wavelength Indicated for use in photodisruption of ocular tissue using laser energy emitted by a Nd: YAG laser. These indications include:
- discission of the posterior capsule of the eye (posterior capsulotomy) and;
- discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients.
b. Ultima 2000/Ultima 2000SE Indicated for use in the treatment of ocular pathology using blue-green and green argon laser energy. These indications include:
- photocoagulation of both anterior and posterior segments including:
- iridotomy, iridectomy and trabeculoplasty in angle closure glaucoma and open angle glaucoma;
- retinal photocoagulation, panretinal photocoagulation and intravitreal endophotocoagulation of vascular and structural abnormalities of the retina and choroid including;
- diabetic retinopathy;
- choroidal neovascularization;
- branch retinal vein occlusion;
- subretinal neovascularization in disciform macular degeneration. - Laser Indirect Ophthalmoscope is indicated for use in the following ophthalmic treatments:
- diabetic retinopathy (pan-retinal photocoagulation);
- retinopexy;
- segmental peripheral photocoagulation;
- segmental photocoagulation;
- cloudy vitreous cavities; and,
- pediatric retinal repairs (under general anesthesia).
- Acculite Endoprobe is indicated for use in the following ophthalmic applications:
- photocoagulation of the anterior and posterior segment, including:
- anterior segment treatment in the surgical management of glaucoma;
- endophotocoagulation in vitreoretinal surgery including panretinal photocoagulation, retinopexy, and treatment of neovascularization.
- photocoagulation of the anterior and posterior segment, including:
Product codes (comma separated list FDA assigned to the subject device)
GEX
Device Description
The Coherent Popeye Ophthalmic Laser is intended to be used to deliver Q-switched Nd:YAG laser energy for use in photodisruption of ocular tissue, including: discission of the posterior capsule of the eye (posterior capsulotomy) discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients. The Coherent Popeye Ophthalmic Laser when used in combination with a Coherent Ultima 2000 or Ultima 2000SE Argon Laser Photocoagulator is intended to be used to deliver argon laser energy for use in the treatment of ocular pathology.
The Coherent Popeye Ophthalmic Lasers are comprised of the following main components:
- a laser/optics module: .
- a laser power supply/control console; .
- a remote control unit; .
- a covered footswitch; .
- a laserized mirror. ●
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Ocular (eye), retina, choroid
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
P830054/S13, S14, S17-S19, S22; K893987; K901481; P840012, K885164; K926452; K897099; K893709, P830054/S22; K913127; K901481
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
0
Attachment 18 510(k) Summary Statement for the Coherent Popeye Ophthalmic Lasers
DEC - 9 1997
K973470
I. General Information
Submitter: Coherent Medical Group 3270 West Bayshore Road Palo Alto, CA 94303
Contact Person: Karen L. Baker
Summary Preparation Date: September 10, 1997
II. Names
Device Names:
Coherent Popeye Ophthalmic Laser
Coherent Popeye Ophthalmic Laser in combination with the Coherent Ultima 2000 Argon Laser Photocoagulator
Coherent Popeye Ophthalmic Laser in combination with the Coherent Ultima 2000SE Argon Laser Photocoagulator
Primary Classification Name: Nd: YAG laser for posterior capsulotomy; and Ophthalmic laser
III. Predicate Devices
Coherent 7970 Nd: YAG Laser (P830054/S13, S14, S17-S19, S22); Coherent 7901 Nd: Y AG Laser (P830054/S13, S14, S17-S19, S22); Nidek YC-1200 Ophthalmic Y AG Laser (K893987; K901481); Lasag Microruptor 2 Nd: Y AG Ophthalmic (P840012, K885164); Zeiss Visulas YAG II Laser (K926452); Alcon 3000LE Nd: YAG Ophthalmic Laser System (K897099); Coherent Novus 2000/ Nd: YAG Laser System (K893709, P830054/S22); Ultima 2000 and 2000SE Argon Laser Photocoagulators (K913127); Nidek Ophthalmic Models YC-1200/Photocoagulator Combination Ophthalmic Laser (K901481).
1
IV. Product Description
The Coherent Popeye Ophthalmic Laser is intended to be used to deliver Q-switched Nd:YAG laser energy for use in photodisruption of ocular tissue, including: discission of the posterior capsule of the eye (posterior capsulotomy) discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients. The Coherent Popeye Ophthalmic Laser when used in combination with a Coherent Ultima 2000 or Ultima 2000SE Argon Laser Photocoagulator is intended to be used to deliver argon laser energy for use in the treatment of ocular pathology.
The Coherent Popeye Ophthalmic Lasers are comprised of the following main components:
- a laser/optics module: .
- a laser power supply/control console; .
- a remote control unit; .
- a covered footswitch; .
- a laserized mirror. ●
V. Indications for Use
The Coherent Popeye Ophthalmic Lasers are indicated for use in the photodisruption of ocular tissue using laser energy emitted by a Nd:YAG laser. These indications include: discission of the posterior capsule of the eye (posterior capsulotomy) and; discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients. The Coherent Popeye Ophthalmic Laser when used in combination with the Coherent Ultima 2000 or Ultima 2000SE has the capability of delivering argon laser energy. The Coherent Ultima 2000 and Ultima 2000SE are indicated for use in the treatment of ocular pathology using blue-green and green argon laser energy.
VI. Rationale for Substantial Equivalence
The Coherent Popeye Ophthalmic Lasers share indications for use, similar design features (including control system, wavelengths, laser mode structure, laser active medium, cooling system, aiming beams, and controls and displays), functional features (including pulse energy, power, repetition rates, burst mode, pulse interval, spot sizes, laser energy delivery control (footswitch), and type of delivery systems) and therefore are substantially equivalent to, the predicate devices referenced in Section III.
VII. Safety and Effectiveness Information
System and software hazard analysis information and software verification and validation information was submitted in conjunction with this Premarket Notification submission. The determination of substantial equivalence was based
2
upon the comparison of the technical characteristics between the Coherent Popeye Ophthalmic Lasers and the predicate laser systems.
VIII. Conclusion
:
The Coherent Popeye Ophthalmic Lasers were found to be substantially equivalent to similar predicate laser devices. The Coherent Popeye Ophthalmic Lasers share the same indications for use, similar design features, and similar functional features as the predicate ophthalmic laser systems.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three lines representing its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ms. Karen Baker Sr. Manager, Regulatory Affairs Coherent Medical Group 3270 West Bayshore Road P. O. Box 10122 Palo Alto, California 94303-0810
DEC - 9 1997
Re: K973470
Trade Name: Coherent Popeye Nd: YAG Ophthalmic Laser and Accessories Coherent Popeye Nd:YAG Laser in Combination with an Ultima 2000 or 2000SE Argon Photocoagulator and Accessories Regulatory Class: II Product Code: GEX Dated: September 10, 1997 Received: September 12, 1997
Dear Ms. Baker:
We have reviewed your Section 510(k) notification of intent to market the devices referenced above and we have determined the devices are substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the devices, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your devices are classified (see above) into either class II (Special Controls) or class III (Premarket Approval), they may be subject to such additional controls. Existing major regulations affecting your devices can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements , as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. In addition, FDA may publish further announcements concerning your devices in the Federal Register. Please note: this response to your premarket notification
4
Page 2 - Ms. Baker
submissions does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your devices as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your devices to a legally marketed predicate device results in a classification for your devices and thus, permits your devices to proceed to the market.
If you desire specific advice for your devices on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your devices, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely vours,
Sincerely, yours,
M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Attachment 2 Indications for Use Statement as Requested by FDA
| 510(K) Number (if Known): | K973470 |
|---|---|
| --------------------------- | --------- |
Device Name: Coherent Popeye Nd: YAG Ophthalmic Laser Coherent Popeye Nd: YAG Laser in Combination with an Ultima 2000 or 2000SE Argon Photocoagulator
Indications for Use:
- The Coherent Popeye Ophthalmic Laser is indicated for use in photodisruption of a. ocular tissue using laser energy emitted by a Nd: YAG laser. These indications include:
discission of the posterior capsule of the eye (posterior capsulotomy) discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients
*** Indications for Use Continued on Next Page ***
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Dental, Infection Control,
and General Hospital Devices
510(k) Number (973470
Prescription Use: X OR Over-The-Counter Use: __
Optional Format 1-2-96
(Per 21 CFR 801.109)
6
Attachment 2 - Continued Indications for Use Statement as Requested by FDA
510(K) Number (if Known): __
Device Name: Coherent Popeye Nd: YAG Ophthalmic Laser Coherent Popeye Nd: YAG Laser in Combination with an Ultima 2000 or 2000SE Argon Photocoagulator
The Coherent Popeye Ophthalmic Laser in Combination with the Ultima 2000 or Ultima 2000SE Argon Photocoagulator is indicated for:
- a. Popeye Nd: Y AG 1064 nm wavelength Indicated for use in photodisruption of ocular tissue using laser energy emitted by a Nd: YAG laser. These indications include:
- discission of the posterior capsule of the eye (posterior . capsulotomy) and;
- discission of pupillary membranes (pupillary membranectomy) ● in aphakic and pseudophakic patients.
- b. Ultima 2000/Ultima 2000SE Indicated for use in the treatment of ocular pathology using blue-green and green argon laser energy. These indications include:
- photocoagulation of both anterior and posterior segments . including:
- iridotomy, iridectomy and trabeculoplasty in angle closure ● glaucoma and open angle glaucoma;
- retinal photocoagulation, panretinal photocoagulation and ● intravitreal endophotocoagulation of vascular and structural abnormalities of the retina and choroid including;
- diabetic retinopathy;
- choroidal neovascularization;
- branch retinal vein occlusion;
- subretinal neovascularization in disciform macular degeneration.
- photocoagulation of both anterior and posterior segments . including:
(Division Sign-Off)
Division of General Restorative Devices
510(k) Number. K973470
Prescription Use
(Per 21 CFR 801.109)
7
Attachment 2 - Continued
Indications for Use Statement as Requested by FDA
510(K) Number (if Known):
Device Name: Coherent Popeye Nd: YAG Ophthalmic Laser Coherent Popeye Nd: YAG Laser in Combination with an Ultima 2000 or 2000SE Argon Photocoagulator
The Coherent Popeye Ophthalmic Laser in Combination with the Ultima 2000 or Ultima 2000SE Argon Photocoagulator (Indications continued)
Laser Indirect Ophthalmoscope
The Laser Indirect Ophthalmoscope is indicated for use in the following ophthalmic treatments:
- . diabetic retinopathy (pan-retinal photocoagulation);
- . retinopexy:
- . segmental peripheral photocoagulation;
- . segmental photocoagulation;
- cloudy vitreous cavities; and, .
- pediatric retinal repairs (under general anesthesia) .
Acculite Endoprobe
The Acculite Endoprobe is indicated for use in the following ophthalmic applications:
- photocoagulation of the anterior and posterior segment, including: ●
- anterior segment treatment in the surgical management of glaucoma;
- endophotocoagulation in vitreoretinal surgery including panretinal photocoagulation, retinopexy, and treatment of neovascularization.
Prescription Use
(Per 21 CFR 801.109)
tcolla